Biocon would be making at least $10 million profit from pegfilgrastim in the next financial year, said Surya Narayan Patra of PhillipCapital.
In a major boost, Biocon-Mylan have received approval for their first biosimilar of cancer medicine pegfilgrastim from the USFDA for selling in the American market.
"It’s a big milestone for Biocon," said Patra. "Given the earlier indication by the management, possibly in the second half of the current calendar year, they would be launching the product. So, practically this is FY20 big product opportunity.”
Biocon-Mylan alliance possibly would be making $150-200 million kind of revenue out of the product opportunity in next financial year, added Patra.